1 / 11

CORPORATE INNOVATION AS AN ENGINE FOR CHANGE: Molecular Diagnostics

CORPORATE INNOVATION AS AN ENGINE FOR CHANGE: Molecular Diagnostics. David Okrongly, Ph.D. SVP Molecular Diagnostics Siemens Healthcare. The Era of the Integrated Diagnostics Company is Here. In Vivo Diagnostics (Major Medical Imaging Systems). Ultrasound. X-ray. Magnetic Resonance.

cesparza
Download Presentation

CORPORATE INNOVATION AS AN ENGINE FOR CHANGE: Molecular Diagnostics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CORPORATE INNOVATION ASAN ENGINE FOR CHANGE:Molecular Diagnostics David Okrongly, Ph.D. SVP Molecular Diagnostics Siemens Healthcare

  2. The Era of the Integrated Diagnostics Company is Here In Vivo Diagnostics (Major Medical Imaging Systems) Ultrasound X-ray Magnetic Resonance Computed Tomography Molecular Imaging Preclinical Imaging Healthcare IT Integrated medical data translated into actionable knowledge In Vitro Diagnostics (Major Medical Laboratory Systems) Urinalysis Molecular Hematology LabAutomation Immunoassay ClinicalChemistry Blood Gas

  3. New science and aging population further burden spending Are we utilizing the Diagnostic Toolbox well? $US Bil 15% 4% Global Diagnostics Global Health Care Healthcare spent on IVD Clinical decision contribution Source: World Medical Markets Fact Book 2007, SG Cowen, Kalorama, TriMark, Management Estimate Global health care spending is accelerating Source: SG Cowen 70% <2%

  4. INT NNRTI NNRTI EI EI INT PI EI PI NRTI INT NRTI NRTI PI NRTI EI Highly Active Antiretroviral Drug Therapy H A A R T COMBO TX NEW Most common

  5. Cancer Represents a Much More Challenging Picture Monoclonal Antibodies Small Molecule Inhibitors

  6. How to treat Node Negative Breast Cancer … NT BasicRiskCategoriesofNode-negative Breast Cancer Patients without treatment Current Treatment according to Guidelines • Molecular markers like Ki67, ErbB2, … Treatment decisions according to molecular classification

  7. Risk of MI Cardiac Risk Assessment # of MIs ~33% ~33% ~33% High risk 7.5% 15% Intermediate risk 77.5% Low risk How??? Molecular Diagnostics

  8. Knowledge-Driven IT Molecular Imaging In Vitro Diagnosis Systems Biomarkers Clinical Applications Visualize and localize molecular processes in vivo for diagnosis and therapy The Era of Molecular Medicine Molecular Medicine Systems Assays IT Applications Leverage novel molecular technologies for risk assessment, early detection and diagnosis of disease Integrate medical information and enable knowledge-driven clinical applications

  9. TRANSFORMING PATHOLOGY:Emerging technology driving practice innovation

More Related